Puma Biotechnology, Inc.

PBYINASDAQHealthcare● Active

$6.85

$-0.18(-2.56%)

Market Cap$348661274

P/E Ratio—

52W High$7.9

52W Low$3.03

Avg Volume278K

Open$7.17

Beta1.21

Free Cash Flow Financials Revenue

Puma Biotechnology, Inc. (PBYI) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PBYI · free cash flow · updated Jun 9, 2026

Core FCF metrics

PBYI · FCF · TTM · margin & CAGR

Free cash flow was $41.7M for FY2025 (fiscal year ending 2025-12-31), up 7.4% year-over-year The FCF margin was 18.3%.

FY2025 Free Cash Flow$41.7M▲ +7.4% YoY

Trailing 12M (TTM)$53.6Mtrailing 4 quarters sum

FCF Margin18.3%$41.7M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PBYI · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$41.8M(0M)$41.7M▲ +7.4%18.3%

FY2024$38.9M(0M)$38.9M▲ +170.5%16.9%

FY2023$27.0M(13M)$14.4M▲ +162.9%6.1%

FY2022−$15.8M(7M)−$22.8M▼ 210.5%-10.0%

FY2021$20.6M(0M)$20.6M▲ +207.3%8.2%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PBYI · P/FCF · FCF yield · FCF per share

Puma Biotechnology, Inc. (PBYI) trades at a FCF yield of 15.37% and a price-to-free-cash-flow ratio of 6.4x. FCF per share stands at $1.07, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

15.37%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.07

TTM FCF ÷ Shares Outstanding

Price / FCF

x6.4

Share Price ÷ FCF per Share

EV / FCF (TTM)

x6.1

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

PBYI · cash flow statement · operating / investing / financing

For FY2025, Puma Biotechnology, Inc. generated $41.8M in operating cash flow and spent 0M in capital expenditures, yielding $41.7M in free cash flow.

Operating Activities

+$41.8M

Cash from core business operations

2025-12-31

Investing Activities

−$36.2M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$45.2M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($41.8M) − |CapEx| (0M) = FCF ($41.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PBYI vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Puma Biotechnology, Inc.YOU

PBYI

$41.7M+7.4%18.3%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Puma Biotechnology, Inc. (PBYI) reported free cash flow of $41.7M for FY2025 (fiscal year ending 2025-12-31), up 7.4% year-over-year. The FCF margin was 18.3%.

Based on available data, Puma Biotechnology, Inc. has maintained positive free cash flow for at least 5 fiscal year(s). FCF peaked at $41.7M in FY2025.

Puma Biotechnology, Inc.'s FCF yield is 15.37% and price-to-FCF ratio is 6.4x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PBYI free cash flow · 8 questions

Puma Biotechnology, Inc. free cash flow was $41.7M for FY2025, up 7.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $53.6M.

PBYI free cash flowPBYI FCFPBYI FCF 2025PBYI free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Puma Biotechnology, Inc. · Puma Biotechnology, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026